GENE ONLINE|News &
Opinion
Blog

2018-05-29| ChinaFundingStartups

Beijing AI+Blockchain Pharma Startup Received Millions of USD Pre-A Financing

by GeneOnline
Share To

Deep Intelligent Pharma (DIP), a company integrating artificial intelligent (AI) technology with pharmaceutical development, received millions of US dollar from ZhenFund, a Beijing-based seed capital, in its pre-A round financing last December. This message was released by a spokesperson at DIP on May 24.

By Joanne Shih

DIP is a technology start-up launched in Beijing in October 2017, applying AI and blockchain technologies to facilitate drug discovery, development, and medical regulatory affairs. Established in China, the company sets its headquarters in Beijing, but branches in both China and the US with offices in Shanghai, Shenyang, Boston, and Silicon Vally. Currently, DIP has over 50 full-time employees.

The company has launched around ten products and collaborated with several Chinese, Asia Pacific, and global pharmaceutical companies since its establishment. Aiming to empower advancement in medical and pharmaceutical industries, DIP has six major product lines which respectively are: 1) Intelligent Pharmacovigilance, 2) A.I.M AI IN MEDICAL, 3) A Blockchain-based, Patient-research Ecosystem, 4) Intelligent Medical Writing, 5) Medical Translations, and 6) Intelligent Regulatory Affairs Solution. Among these products, AI and blockchain play a pivot role in creating new platforms for medical and clinical research and in allowing medical data to be used appropriately.

Emma Yin, Investment Vice President at ZhenFund, said, “DIP is formed by a talented pool from international pharmaceutical giants including Johnson & Johnson, Pfizer, Eli Lilly, Novartis, as well as AI algorithmists from Alibaba and experts in natural language processing. It is a true combination of AI technology and drug R&D. Therefore, DIP has the potential to develop viable solutions and meet demands in pharmaceutical market.”

Reference

https://ibmi.taiwan-healthcare.org/news_detail.php?REFDOCTYPID=&REFDOCID=0p99g009btfcwvn

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
BIODND – An AI-Powered Database That Breaks New Ground in Life Science Business Development
2023-11-29
GeneOnline’s Weekly News Highlights: Oct 30-Nov 3
2023-11-07
GeneOnline’s Weekly News Highlights: Oct 16-Oct 20
2023-10-24
LATEST
BIODND – An AI-Powered Database That Breaks New Ground in Life Science Business Development
2023-11-29
GeneOnline’s Weekly News Highlights: Nov 20-Nov 24
2023-11-27
SK Bioscience and Hilleman Laboratories Join Forces for Ebola Vaccine Development
2023-11-23
BeiGene to Expand Oncology Pipeline Through ENSEM Therapeutics Partnership
2023-11-23
Advancing the Frontiers of Cell and Gene Therapy – An Interview with Dr. Shin Kawamata
2023-11-21
Astellas and Pfizer’s Drug Receives FDA Approval as Treatment for High-Risk Prostate Cancer Recurrence
2023-11-21
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
2023-11-20
EVENT
2023-11-30
2023 Healthcare+ EXPO・Taiwan
Taipei , Taiwan
Scroll to Top